LONDON, UK, 4 March 2025 - In a comprehensive Genomic Press Viewpoint (review) article, researchers are shining a spotlight on a revolutionary approach to tackling neuroendocrine tumours (NETs), a ...
In a comprehensive Genomic Press Viewpoint (review) article, researchers are shining a spotlight on a revolutionary approach to tackling neuroendocrine tumors (NETs), a rare but increasingly prevalent ...
JNJ-6420 is an anti-hK2 antibody–based targeted radioligand therapy that delivers a high-energy short-range alpha-particle emitter to prostate cancer cells. (wildpixel/iStock/Getty Images Plus) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results